Trial Profile

A Randomized Phase II Trial of R-HCVAD/MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant Vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Patients <= 65 Years of Age With Previously Untreated Mantle Cell Lymphoma.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Etoposide; Folinic acid; Folinic acid; Methotrexate; Rituximab; Vincristine
Indications Mantle-cell lymphoma
Focus Therapeutic Use

14 May 2021 Biomarkers information updated
21 Jun 2012 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University; SWOG1106).
10 Jun 2012 Additional lead trial investigator (Ramchandren Radhakrishnan) identified as reported by Barbara Ann Karmanos Cancer Institute.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com